GeNeuro S.A. (Euronext Paris: GNRO)

https://www.geneuro.com

GeNeuro was created in 2006 by Eclosion, the Geneva life sciences accelerator, as a spin-off of Institut Mérieux of France. It develops first-in-class therapies against diseases associated with the expression of pathogenic proteins of human endogenous retroviral origin (HERV). GeNeuro’s lead product, GNbAC1, is a therapeutic antibody that targets MSRV-Env, a protein expressed in Multiple Sclerosis (MS) lesions from an early stage, which has been shown to be both pro-inflammatory and an inhibitor of remyelination, the two major drivers of MS progression. The Multiple Sclerosis associated retrovirus (MSRV) is normally latent in the genome of individuals, but it can be re-activated by viral infections and other co-factors to express a pathogenic protein, MSRV-Env. MSRV-Env provides a missing link between the observation that viral infections are associated with the onset of the disease and expression of the pathogenic factor (the MSRV-Env protein), which can then explain the inflammatory and demyelinating characteristics of MS. By targeting a potential key factor present in all types of MS that fuels both inflammation and neurodegeneration, GeNeuro aims to bring to patients a safe, long-term treatment with the potential to reduce or stop progression of the disease. As the first drug intended to address a potential causal factor of the disease, it may radically change the way MS patients are treated. *

	Start	2006-01-01 established
	Industry	CNS drug (neurological drug)
	Industry 2	diagnostics (medical/biological)
	Person	Martin-Garcia, Jesús (Eclosion 201207 General Partner + Founder + GeNeuro 201512 CEO)
	Person 2	Curtin, Francois (Geneuro 201207 CEO)

	Region	Plan-les-Ouates GE
	Country	Switzerland
	Street	18 Chemin des Aulx
	City	1228 Plan-les-Ouates GE
	Tel	+41-22-794-5085
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2019-11-25)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for GeNeuro S.A. (Euronext Paris: GNRO)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)